• ABL Texcell Diagnostics' planned acquisition of Vela Diagnostics' Singapore and US operations will not proceed following termination of the letter of intent.
• The deal, announced September 21, 2026, covered 100% of Vela Operations Singapore and Vela Diagnostics USA.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ABL Diagnostics SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20261020409681) on October 20, 2026, and is solely responsible for the information contained therein.